JAMA Oncology· 2017Q1
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
- 3,486citations
- Q1SCImago
- 2017year
Short summary
Neuroendocrine tumor (NET) incidence in the US rose 6.4-fold from 1973 to 2012, reaching 6.98 per 100,000, with a 20-year prevalence of 171,321 by 2014. Overall survival for NETs improved significantly between 2000-2004 and 2009-2012, particularly for distant-stage gastrointestinal and pancreatic NETs.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Epidemiology
EpidemiologyMedicine